Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.72 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.46 |
| ▸ | PPARG | P37231 | 7/20 | 0.46 |
| ▸ | PPARD | Q03181 | 7/20 | 0.46 |
| ▸ | PPARA | Q07869 | 7/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pivalate SCHEMBL4630401 | 0.95 | FFAR3 (0.65) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL3238982 | 0.88 | — | — | |
| Butyric Acid SCHEMBL27718871 | 0.85 | — | — | |
| Butyric Acid SCHEMBL8458708 | 0.85 | FFAR3 (1.00) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL991717 | 0.85 | FFAR3 (1.00) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL5703921 | 0.85 | FFAR3 (1.00) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL1330379 | 0.85 | — | — | |
| Butyric Acid SCHEMBL339305 | 0.85 | FFAR3 (1.00) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL20678495 | 0.85 | — | — | |
| Butyric Acid SCHEMBL4446516 | 0.85 | FFAR3 (1.00) | FFAR3HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2024-06-27 | — | — | US | disclosed |
| EP-4305049-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2024-01-17 | — | — | EP | disclosed |
| US-11844754-B2 | Methods for treatment of Parkinson's disease | NEURODERM, LTD. (IL) | 2023-12-19 | — | — | US | disclosed |
| CN-116964069-A | Stabilized liquid compositions comprising levodopa-tyrosine conjugates and uses thereof | 纽罗德姆有限公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2023126945-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-07-06 | — | — | WO | disclosed |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-05-25 | — | — | US | disclosed |
| EP-4025200-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2022-07-13 | — | — | EP | disclosed |
| CN-114727973-A | Liquid compositions comprising L-dopa amino acid conjugates and uses thereof | 纽罗德姆有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021044420-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2021-03-11 | — | — | WO | disclosed |
| EP-1085012-B1 | PROCESS FOR PRODUCING A PURIFIED PROSTAGLANDIN DERIVATIVE | ASAHI GLASS CO LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
| EP-1924240-A1 | PERSONAL CARE PRODUCTS INCORPORATING CELLULOSIC FATTY ACID ESTERS | EASTMAN CHEMICAL COMPANY (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007033252-A1 | PERSONAL CARE PRODUCTS INCORPORATING CELLULOSIC FATTY ACID ESTERS | EASTMAN CHEMICAL COMPANY (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070053855-A1 | Personal care products incorporating cellulosic fatty acid esters | EASTMAN CHEMICAL COMPANY | 2007-03-08 | — | — | US | disclosed |
| EP-1250342-B1 | BRIDGED METALLOCENE COMPOUNDS AS OLEFIN-POLYMERIZATION CATALYSTS | POLIMERI EUROPA SPA (IT) | 2006-06-28 | — | — | EP | disclosed |
| US-6984703-B1 | Bridged metallocene compounds as olefin-polymerization catalysts | POLIMERI EUROPA S.P.A. (IT) | 2006-01-10 | — | — | US | disclosed |
| US-6632958-B1 | An alkene (1) is added to cyclopentenone (2) under the action of an alkyl lithium and an organic copper reagent to form an adduct, said adduct is reacted with e.g. a carboxylic anhydride (4) to obtain a prostaglandin derivative, which is | MITSUBISHI PHARMA CORPORATION (JP) | 2003-10-14 | — | — | US | disclosed |
| EP-1250342-A1 | BRIDGED METALLOCENE COMPOUNDS AS OLEFIN-POLYMERIZATION CATALYSTS | Polimeri Europa S.p.A. (IT) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001040238-A1 | BRIDGED METALLOCENE COMPOUNDS AS OLEFIN-POLYMERIZATION CATALYSTS | POLIMERI EUROPA S.P.A. (IT) | 2001-06-07 | — | — | WO | disclosed |
| EP-1085012-A1 | PROCESS FOR PRODUCING PURIFIED PROSTAGLANDIN DERIVATIVE | Asahi Glass Co., Ltd. (JP) | 2001-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844754-B2 | Methods for treatment of Parkinson's disease | DDC, DDT, SLC6A3 | FFAR3 2930/4885HDAC3 1634/4885HDAC1 1656/4885 |
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | COMT, TH, DDT | FFAR3 1490/4885HDAC3 3444/4885HDAC1 2761/4885 |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | DDC, DDT, COMT | FFAR3 2930/4885HDAC3 1608/4885HDAC1 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.